PRLD · Insider Trading
Prelude Therapeutics Incorporated
Every open-market purchase and sale reported by PRLD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-10 | Paul A Friedman | Director | A | +38,000 deriv. | — |
| 2026-06-10 | David P Bonita | Director | A | +38,000 deriv. | — |
| 2026-06-10 | Victor Sandor | Director | A | +38,000 deriv. | — |
| 2026-06-10 | Katina Dorton | Director | A | +38,000 deriv. | — |
| 2026-06-10 | Martin Babler | Director | A | +38,000 deriv. | — |
| 2026-06-10 | Julian Baker | Director | A | +456,000 deriv. | — |
| 2026-05-04 | Charles Q Morris | Chief Medical Officer | A | +450,000 deriv. | — |
| 2026-04-28 | Rajeev M. Shah | 10%+ Owner | J | −5,628,000 | — |
| 2026-04-23 | David P Bonita | Director | Buy | +2,815,315 | +$12.50M |
| 2026-04-23 | ORBIMED CAPITAL LLC | Director | Buy | +11,261,260 | +$50.00M |
| 2026-04-22 | BAKER BROS. ADVISORS LP | Director | Buy | +13,513,512 deriv. | — |
| 2026-02-05 | Peggy Scherle | Chief Scientific Officer | A | +230,000 deriv. | — |
| 2026-02-05 | Krishna Vaddi | CEO | A | +837,000 deriv. | — |
| 2026-02-05 | Bryant David Lim | CLO, CFO, Corp Sec. | A | +275,000 deriv. | — |
| 2026-02-05 | Andrew Combs | Chief Chemistry Officer | A | +230,000 deriv. | — |
| 2025-11-07 | Victor Sandor | Director | A | +121,285 deriv. | — |
| 2025-10-20 | Katina Dorton | Director | A | +76,000 deriv. | — |
| 2025-10-07 | Jane Huang | President, CMO | MIXED | +6,020 | −$4.93K |
| 2025-07-08 | Jane Huang | President, CMO | MIXED | +6,020 | −$2.66K |
| 2025-06-13 | Paul A Friedman | Director | A | +38,000 deriv. | — |
| 2025-06-13 | David P Bonita | Director | A | +38,000 deriv. | — |
| 2025-06-13 | Martin Babler | Director | A | +38,000 deriv. | — |
| 2025-06-13 | Victor Sandor | Director | A | +38,000 deriv. | — |
| 2025-06-13 | Mardi Dier | Director | A | +38,000 deriv. | — |
| 2025-06-13 | Baker Brothers Life Sciences LP | Director | A | +912,000 deriv. | — |
| 2025-04-07 | Jane Huang | President, CMO | MIXED | +6,020 | −$2.26K |
| 2025-03-27 | Andrew Combs | Chief Chemistry Officer | Buy | +100,000 | +$69.25K |
| 2025-03-27 | Krishna Vaddi | CEO | Buy | +675,000 | +$467.44K |
| 2025-03-24 | Krishna Vaddi | CEO | Buy | +20,416 | +$14.91K |
| 2025-03-18 | Krishna Vaddi | CEO | Buy | +39,105 | +$29.46K |
| 2025-03-14 | Krishna Vaddi | CEO | Buy | +97,500 | +$69.56K |
| 2025-02-05 | Krishna Vaddi | CEO | A | +496,000 deriv. | — |
| 2025-02-05 | Bryant David Lim | CLO, CFO, Corp Sec. | A | +200,000 deriv. | — |
| 2025-02-05 | Andrew Combs | Chief Chemistry Officer | A | +175,000 deriv. | — |
| 2025-02-05 | Jane Huang | President, CMO | A | +200,000 deriv. | — |
| 2025-02-05 | Peggy Scherle | Chief Scientific Officer | A | +175,000 deriv. | — |
| 2025-01-07 | Jane Huang | President, CMO | MIXED | +5,516 | −$5.36K |
| 2025-01-03 | Krishna Vaddi | CEO | Buy | +5,000 | +$6.04K |
| 2025-01-02 | Krishna Vaddi | CEO | Buy | +10,000 | +$12.00K |
| 2024-12-26 | Andrew Combs | Chief Chemistry Officer | Buy | +63,075 | +$85.54K |
| 2024-12-20 | Krishna Vaddi | CEO | Buy | +106,888 | +$99.33K |
| 2024-12-20 | Bryant David Lim | CLO, Interim CFO, Corp Sec. | Buy | +25,000 | +$22.64K |
| 2024-10-07 | Jane Huang | President, CMO | MIXED | +6,026 | −$6.70K |
| 2024-07-08 | Jane Huang | President, CMO | MIXED | +6,028 | −$12.05K |
| 2024-06-18 | Paul A Friedman | Director | A | +23,500 deriv. | — |
| 2024-06-18 | David P Bonita | Director | A | +23,500 deriv. | — |
| 2024-06-18 | Mardi Dier | Director | A | +23,500 deriv. | — |
| 2024-06-18 | 667, L.P. | Director | A | +282,000 deriv. | — |
| 2024-06-18 | Martin Babler | Director | A | +23,500 deriv. | — |
| 2024-06-18 | Victor Sandor | Director | A | +23,500 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Rajeev M. Shah | 10%+ Owner | 6,475,882 | $23.96M |
| Krishna Vaddi | CEO | 2,422,951 | $8.96M |
| ORBIMED CAPITAL LLC | Director | 1,126,126 | $4.17M |
| David P Bonita | Director | 1,126,126 | $4.17M |
| Paul A Friedman | Director | 500,098 | $1.85M |
| Andrew Combs | Chief Chemistry Officer | 480,123 | $1.78M |
| Peggy Scherle | Chief Scientific Officer | 176,234 | $652.07K |
| Jane Huang | President, CMO | 86,917 | $321.59K |
| Bryant David Lim | CLO, CFO, Corp Sec. | 27,400 | $101.38K |
| Mardi Dier | Director | 10,000 | $37.00K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PRLD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.